Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Gymnema and Reduced Low-Density Lipoprotein Level

Research synthesisModerate evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across all 3 studies, Gymnema supplementation showed beneficial effects on reducing LDL cholesterol, with effect sizes ranging from small to moderate (predominantly moderate). The most studied dose was 300 mg twice daily (600 mg/day), and effects were typically observed at 12 weeks. Evidence comes from clinical populations with metabolic syndrome or impaired glucose tolerance.

  • Effective dose range: 300 mg twice daily (600 mg/day)
  • Studied populations: clinical populations including metabolic syndrome and impaired glucose tolerance

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Most studies lasted 12 weeks; effects with shorter use are not well-documented.

Generated Jun 13, 2026
Doses used in studies
  • mg/day: 600 (median 600, IQR 600–600) — 2 studies
Time to effect
Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 3 studies
3 of 3 papers
Back to top